Detalhe da pesquisa
1.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35139273
2.
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
Int J Cancer
; 2024 May 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38709956
3.
Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
Int J Cancer
; 2024 Apr 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38676430
4.
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
N Engl J Med
; 385(23): 2123-2131, 2021 12 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34874631
5.
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol
; 185: 186-193, 2024 Mar 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38447347
6.
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
Gynecol Oncol
; 183: 25-32, 2024 Mar 14.
Artigo
Inglês
| MEDLINE | ID: mdl-38490057
7.
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
Future Oncol
; 2024 Mar 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38501262
8.
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Int J Gynecol Cancer
; 34(4): 469-477, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38101816
9.
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Int J Gynecol Cancer
; 2024 Apr 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38627035
10.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38129136
11.
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ann Surg Oncol
; 30(1): 35-45, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36085390
12.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol
; 170: 300-308, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36758420
13.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37862791
14.
Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort.
Int J Gynecol Cancer
; 33(1): 1-9, 2023 01 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36356982
15.
Best original research presented at the 23rd European Congress on Gynaecological Oncology-Best of ESGO 2022.
Int J Gynecol Cancer
; 33(2): 175-182, 2023 Feb 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36521934
16.
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.
Int J Gynecol Cancer
; 33(8): 1247-1252, 2023 08 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37068851
17.
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.
Int J Gynecol Cancer
; 33(11): 1733-1742, 2023 11 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37931976
18.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer
; 33(4): 562-570, 2023 04 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36564099
19.
Endometrial carcinosarcoma.
Int J Gynecol Cancer
; 33(2): 147-174, 2023 02 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36585027
20.
Gestational choriocarcinoma.
Int J Gynecol Cancer
; 33(10): 1504-1514, 2023 10 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37758451